A study to evaluate the effect of Lucentis® (Ranibizumab) on Vision Related Function using the VFQ-25 questionnaire in patients with wet age-related macular degeneration (AMD)
Phase 4
- Registration Number
- CTRI/2010/091/000379
- Lead Sponsor
- ovartis health care private limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
1.Diagnosed with choroidal neovascularization (CNV) secondary to (wet) AMD
2.Willing to provide informed consent (as per the local practices)
Patients may have received Lucentis monotherapy or combination therapy [with Visudyne® (verteporfin)]
Exclusion Criteria
1.Hypersensitivity to the active substance or to any of the excipients.
2.Patients with active or suspected ocular or periocular infections.
3.Patients with active intraocular inflammation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method